News und Analysen

Invitae (NYSE: NVTA) recently announced news that made its shares pop. The genetic testing company won a regulatory nod for a first-of-its-kind test for hereditary cancer risk. The U.S. Food and

Shares of Blueprint Medicines (NASDAQ: BPMC) closed up 25.6% on Thursday after the cancer and blood discorder therapy company announced stronger-than-expected quarterly results.

Blueprint Medicines'

Oncology-focused healthcare company Novocure (NASDAQ: NVCR) wasn't much of a cure for anyone's ill finances on Thursday. Its share price dived by nearly 8% on the day after management released its

Shares of LianBio (NASDAQ: LIAN) were skyrocketing 132.4% higher as of 11:11 a.m. ET on Tuesday. The huge gain came after the company announced that it entered into an agreement to hand over

Shares of Revolution Medicines (NASDAQ: RVMD) were crashing 42.5% lower as of 11:13 a.m. ET on Monday. The steep decline came after the oncology company presented results on Sunday for RMC-6236 from

Exelixis (NASDAQ: EXEL) is not exactly a household name in the biotech industry, but that hasn't stopped the company from crushing the market this year -- rising over 30%. Perhaps one key reason

Shares of Revolution Medicines (NASDAQ: RVMD) were up more than 20% as of 2 p.m. ET after the company announced positive phase 1/1b trial data for two cancer therapies. The clinical-stage biotech's

Bristol Myers Squibb (NYSE: BMY) has historically been a growth machine, always on the hunt for acquisitions and ways to get bigger and better. But acquisitions have also been a bit of a necessity

Shares of Tango Therapeutics (NASDAQ: TNGX) were down more than 12% as of 11:15 a.m. on Monday. The healthcare stock is up more than 37% this year.

Tango is a clinical-stage biotech that focuses on

Shares of Invitae (NYSE: NVTA) roared as much as 37% higher early Monday, then settled to trade up 13% as of 3 p.m. ET after the U.S Food and Drug Administration (FDA) authorized marketing efforts

Fool.com contributor Parkev Tatevosian considers Invitae (NYSE: NVTA) stock and its financial prospects to determine if investors should buy the stock.

*Stock prices used were the afternoon prices

Last year was challenging for the stock market. Things have been better since 2023 started, but some equities have even performed pretty well throughout this ordeal. That's the case with Exelixis

Since December 2021, superstar investor Cathie Wood has been adding to her position in genetic-testing company Invitae (NYSE: NVTA) while many investors were doing just the opposite. The stock has

Catalent (NYSE: CTLT) is one company that probably wishes the summer would never end. As August came to a close, the contract drug manufacturer's stock enjoyed a nearly 12% rise over the course of

Shares of Novocure (NASDAQ: NVCR) are down 25.9% so far this week as of the market close on Thursday, according to data provided by S&P Global Market Intelligence, as the company announced a

Investing in stocks isn't just for the rich and famous since quality stocks can be found at almost any price. Some are trading for well above $1,000 per share, while others go for less than $100

Contract drug manufacturer Catalent (NYSE: CTLT) provided some very effective medicine to its investors on Tuesday. The company's shares leaped almost 5% higher following the publication of its

Shares of Invitae (NYSE: NVTA) were crashing 19.4% lower as of 12:13 p.m. ET on Thursday. The decline came on the heels of two developments.

Invitae revealed in a regulatory filing on Wednesday that

Following the market's gloomy 2022, this year has been a breath of fresh air with the S&P 500 rising 14% so far in 2023. Some biotech stocks have soared even higher thanks to strong products. Cystic

News from the Food and Drug Administration (FDA) can often make or break a stock. This month, it broke Sage Therapeutics (NASDAQ: SAGE).

Although the company obtained approval for its depression

Most people have either had cancer themselves or know someone who has. According to the American Cancer Society, 1 in 3 people in the U.S. will be diagnosed with one of the numerous forms of cancer.

Fool.com contributor Parkev Tatevosian offers investors an earnings review of Invitae (NYSE: NVTA) and lets you know if the beaten-down growth stock is a buy.

*Stock prices used were the afternoon

Shares of Mirati Therapeutics (NASDAQ: MRTX) are up more than 27% as of 10:25 a.m. ET. The company released earnings after the markets closed on Tuesday. The healthcare stock is down more than 21%

Image source: The Motley Fool.

Invitae (NYSE: NVTA)Q2 2023 Earnings CallAug 08, 2023, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Cancer-focused biotech Novocure (NASDAQ: NVCR) was the focus of an analyst upgrade on Tuesday, and the stock benefited from the move. In late-session trading that day, it was up by more than 3.3% in